Aviceda Therapeutics
Founded 2019 · CIK 0001824762 · Biotech · Private
siglec-binding glycan nanoparticle therapeutic for geographic atrophy
avicedatx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $99M
- 7 Form D · Nov 2024
- 23 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $4,250,000 | |
| Private capital raised | Form D · SEC | $1,950,000 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $49,450,983 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $8,398,584 | |
| Private capital raised | Form D · SEC | $15,610,000 | |
| Private capital raised | Form D · SEC | $18,899,969 | |
| Private capital raised | Form D · SEC | $200,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1751 | ANTHROBIO, INC. | — | — |
| 1752 | Torque Medical Holdings, LLC | — | $4.7M |
| 1753 | Navitor Pharmaceuticals | — | $65M |
| 1754 | Aviceda Therapeutics | — | $99M |
| 1755 | PROTABIT, LLC | — | — |
| 1756 | LAMNOTHERAPEUTICS, INC. | — | — |
| 1757 | REACTIVE BIOSCIENCES INC | — | $43M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Christoph AdamsDirector
- Kyrylo BigayDirector · Executive Officer
- David CallananExecutive Officer
- Ross DarwinDirector
- Mohamed GeneadDirector · Executive Officer
- Mariusz GralewskiDirector
- David GuyerDirector
- Tarek HassanExecutive Officer
- Patrick JohnsonDirector
- Robert KniazDirector
- Derek KunimotoDirector · Executive Officer
- Erin LavelleDirector
- Nancy ThomasonDirector
- Michael TolentinoDirector · Executive Officer
- Dmytro VoloshynDirector
- Paul VukelicDirector
- Jay WoodsDirector
Patents
- Sialic-acid Ligand Decorated Therapeuticsapplication
- Polysialic Acid-polymer Conjugate And Nanoparticleapplication
- Polysialic Acid-polymer Conjugate And Nanoparticleapplication
- Polysialic Acid-polymer Conjugate And Nanoparticleapplication
- Polysialic Acid-polymer Conjugate And Nanoparticleapplication
- Glycomimetic Ligandsapplication
- Polysialic Acid-polymer Conjugate And Nanoparticleapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.